New options and old dilemmas in the treatment of patients with advanced colorectal cancer

被引：93

作者：

Punt, CJA ^{[1
]}

机构：

[1] Radboud Univ Nijmegen Med Ctr, Dept Med Oncol, NL-6500 HB Nijmegen, Netherlands

来源：

ANNALS OF ONCOLOGY | 2004年 / 15卷 / 10期

关键词：

bevacizumab; capecitabine; cetuximab; colorectal cancer; irinotecan; oxaliplatin;

D O I：

10.1093/annonc/mdh383

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

With more data on the use of oxaliplatin and irinotecan available, and the recent approval of two signal transduction inhibitors for patients with advanced colorectal cancer, there are now many treatment options to choose from. From the current regimens no straightforward choice can be made that provides any patient with the optimal chance for prolonged survival with the least side-effects. The current data concerning timing and duration of chemotherapy, combination or sequential therapy, preference of agents for first-line treatment, oral fluoropyrimidines, neo-adjuvant chemotherapy for irresectable liver metastases, and the use of signal transduction inhibitors are reviewed.

引用

页码：1453 / 1459

页数：7

共 50 条

[21] A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer [J].

Goldberg, RM ;

Sargent, DJ ;

Morton, RF ;

Fuchs, CS ;

Ramanathan, RK ;

Williamson, SK ;

Findlay, BP ;

Pitot, HC ;

Alberts, SR .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :23-30

[22] Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment [J].

Grothey, A ;

Sargent, D ;

Goldberg, RM ;

Schmoll, HJ .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1209-1214

[23]

GROTHEY A, 2003, EJC SUPPL, V90, pS90

[24] Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study [J].

Hoff, PM ;

Ansari, R ;

Batist, G ;

Cox, J ;

Kocha, W ;

Kuperminc, M ;

Maroun, J ;

Walde, D ;

Weaver, C ;

Harrison, E ;

Burger, HU ;

Osterwalder, B ;

Wang, AO ;

Wong, R .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2282-2292

[25] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].

Hurwitz, H ;

Fehrenbacher, L ;

Novotny, W ;

Cartwright, T ;

Hainsworth, J ;

Heim, W ;

Berlin, J ;

Baron, A ;

Griffing, S ;

Holmgren, E ;

Ferrara, N ;

Fyfe, G ;

Rogers, B ;

Ross, R ;

Kabbinavar, F .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342

[26] Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer:: European organization of research and treatment of cancer gastrointestinal group study 40952 [J].

Köhne, CH ;

Wils, J ;

Lorenz, M ;

Schöffski, P ;

Voigtmann, R ;

Bokemeyer, C ;

Lutz, M ;

Kleeberg, U ;

Ridwelski, K ;

Souchon, R ;

Ei-Serafi, M ;

Weiss, U ;

Burkhard, O ;

Rückle, H ;

Lichinitser, M ;

Langenbuch, T ;

Scheithauer, W ;

Baron, B ;

Couvreur, ML ;

Schmoll, HJ .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (20) :3721-3728

[27] Pharmacogenomics in colorectal cancer [J].

Lenz, HJ .

SEMINARS IN ONCOLOGY, 2003, 30 (04) :47-53

[28] Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer [J].

Levi, F ;

Zidani, R ;

Misset, JL .

LANCET, 1997, 350 (9079) :681-686

[29] Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial [J].

Maughan, TS ;

James, RD ;

Kerr, DJ ;

Ledermann, JA ;

Seymour, MT ;

Topham, C ;

McArdle, C ;

Cain, D ;

Stephens, RJ .

LANCET, 2003, 361 (9356) :457-464

[30] European Organisation for Research and Treatment of Cancer's point of view [J].

Meunier, F ;

Lacombe, D .

LANCET, 2003, 362 (9384) :663-663

← 1 2 3 4 5 →